Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147127 | 1.00 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL29978733 | 1.00 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL147503 | 0.95 | IDO1 (0.44) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL147502 | 0.95 | IDO1 (0.44) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL30448914 | 0.91 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL30449652 | 0.91 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL147069 | 0.91 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL147068 | 0.91 | IDO1 (0.49) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL20198880 | 0.89 | IDO1 (0.47) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL20198881 | 0.88 | IDO1 (0.46) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525803-B1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS INC (US) | 2022-12-07 | — | — | EP | claimed |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2020-05-19 | — | — | US | claimed |
| US-20200054673-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | JUNO THERAPEUTICS, INC. (US) | 2020-02-20 | — | — | US | claimed |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2019-10-03 | — | — | US | claimed |
| US-20190270812-A1 | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER | INCYTE CORP (US) | 2019-09-05 | — | — | US | claimed |
| EP-2824100-B1 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | claimed |
| EP-3102237-A1 | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER | Incyte Corporation (US) | 2016-12-14 | — | — | EP | claimed |
| WO-2015119944-A1 | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER | INCYTE CORPORATION (US) | 2015-08-13 | — | — | WO | claimed |
| EP-2315756-B9 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-07-22 | — | — | EP | claimed |
| US-8993605-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | claimed |
| EP-2315756-B1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2014-09-03 | — | — | EP | claimed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | claimed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | claimed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | claimed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | claimed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| JP-2011527686-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2315756-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | claimed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270812-A1 | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER | IDO1, IDO2, CD274 | IDO1 1/4885CYP3A4 3139/4885CYP2C9 3510/4885 |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20200054673-A1 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | KYNU, IDO1, IDO2 | IDO1 2/4885CYP3A4 1445/4885CYP2C9 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.